- Home
- RSLS vs SCNI Comparison
RSLS vs SCNI Comparison
Compare RSLS & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- SCNI
- Stock Information
- Founded
- RSLS 2002
- SCNI 2003
- Country
- RSLS United States
- SCNI Israel
- Employees
- RSLS N/A
- SCNI N/A
- Industry
- RSLS Medical/Dental Instruments
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RSLS Health Care
- SCNI Health Care
- Exchange
- RSLS Nasdaq
- SCNI Nasdaq
- Market Cap
- RSLS 4.5M
- SCNI 3.2M
- IPO Year
- RSLS 2007
- SCNI N/A
- Fundamental
- Price
- RSLS $2.44
- SCNI N/A
- Analyst Decision
- RSLS Hold
- SCNI
- Analyst Count
- RSLS 1
- SCNI 0
- Target Price
- RSLS N/A
- SCNI N/A
- AVG Volume (30 Days)
- RSLS 4.5M
- SCNI 1.1M
- Earning Date
- RSLS 08-13-2025
- SCNI 08-14-2025
- Dividend Yield
- RSLS N/A
- SCNI N/A
- EPS Growth
- RSLS N/A
- SCNI N/A
- EPS
- RSLS N/A
- SCNI N/A
- Revenue
- RSLS $7,175,000.00
- SCNI $658,000.00
- Revenue This Year
- RSLS $52.80
- SCNI N/A
- Revenue Next Year
- RSLS N/A
- SCNI N/A
- P/E Ratio
- RSLS N/A
- SCNI N/A
- Revenue Growth
- RSLS N/A
- SCNI N/A
- 52 Week Low
- RSLS $2.23
- SCNI $1.90
- 52 Week High
- RSLS $414.99
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- RSLS 36.20
- SCNI 42.95
- Support Level
- RSLS $2.37
- SCNI $2.12
- Resistance Level
- RSLS $2.46
- SCNI $2.85
- Average True Range (ATR)
- RSLS 0.22
- SCNI 0.20
- MACD
- RSLS 0.20
- SCNI 0.00
- Stochastic Oscillator
- RSLS 2.96
- SCNI 11.37
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.